Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Alberto Pavan[1], Andrea Boscolo Bragadin[2], Lorenzo Calvetti[3], Alessandra Ferro[1,2], Elisabetta Zulato[4], Ilaria Attili[1,2], Giorgia Nardo[4], Alessandro Dal Maso[1,2], Stefano Frega[1], Andrea Giovanni Menin[5], Matteo Fassan[6], Fiorella Calabrese[7], Giulia Pasello[1], Valentina Guarneri[1,2], Giuseppe Aprile[3], PierFranco Conte[1,2], Rafael Rosell[8], Stefano Indraccolo[4], Laura Bonanno[1]

[1]Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy; [2]Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy; [3]Department of Oncology, San Bortolo General Hospital, ULSS8 Berica - East District, Vicenza, Italy; [4]Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy; [5]Department of Pathology, San Bortolo General Hospital, ULSS8 Berica - East District, Vicenza, Italy; [6]Department of Medicine, Surgical Pathology and Cytopathology Unit, Università degli Studi di Padova, Padova, Italy; [7]Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Università degli Studi di Padova, Padova, Italy; [8]Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias I Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain

Contributions: (I) Conception and design: L Bonanno, S Indraccolo, A Pavan; (II) Administrative support: L Bonanno, S Indraccolo, V Guarneri, P Conte; (III) Provision of study materials or patients: L Bonanno, L Calvetti, G Pasello, I Attili, A Pavan; (IV) Collection and assembly of data: L Bonanno, A Pavan; (V) Data analysis and interpretation: A Boscolo Bragadin, E Zulato, G Nardo, S Indraccolo, L Bonanno, A Pavan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Laura Bonanno. Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. Email: laura.bonanno@iov.veneto.it.

Background: Characterization of tumor-related genetic alterations is promising for the screening of new predictive markers in non-small cell lung cancer (NSCLC). Aim of the study was to evaluate prognostic and predictive role of most frequent tumor-associated genetic alterations detected in plasma before starting immune checkpoint inhibitors (ICIs).

Methods: Between January 2017 and October 2019, advanced NSCLC patients were prospectively screened with plasma next-generation sequencing (NGS) while included in two trials: VISION (NCT02864992), using Guardant360® test, and MAGIC (Monitoring Advanced NSCLC through plasma Genotyping during Immunotherapy: Clinical feasibility and application), using Myriapod NGS-IL 56G Assay. A control group of patients not receiving ICIs was analyzed.

Results: A total of 103 patients receiving ICIs were analyzed: median overall survival (OS) was 20.8 (95% CI: 16.7–24.9) months and median immune-related progression free disease (irPFS) 4.2 (95% CI: 2.3–6.1) months. TP53 mutations in plasma negatively affected OS both in patients treated with ICIs and in control group (P=0.001 and P=0.009), indicating a prognostic role. STK11 mutated patients (n=9) showed a trend for worse OS only if treated with ICIs. The presence of KRAS/STK11 co-mutation and KRAS/STK11/TP53 co-mutation affected OS only in patients treated with ICIs (HR =10.936, 95% CI: 2.337–51.164, P=0.002; HR =17.609, 95% CI: 3.777–82.089, P<0.001, respectively), indicating a predictive role.

Conclusions: Plasma genotyping demonstrated prognostic value of TP53 mutations and predictive value of KRAS/STK11 and KRAS/STK11/TP53 co-mutations.

Keywords: Immunotherapy; lung cancer; predictive biomarkers; circulating tumor DNA; STK11

Introduction

The introduction of immune checkpoint inhibitors (ICIs) in clinical practice has revolutionized the treatment of advanced non-small cell lung cancers (NSCLCs) (1-5). Such agents are monoclonal antibodies acting by boosting immune response against cancer cells (6). ICIs commonly used in clinical practice target the PD-1/PD-L1 axis, either inhibiting PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab and durvalumab). Pembrolizumab is approved as first line treatment for patients with advanced stage NSCLC and tumor cell expression of PD-L1 (tumor proportion score, TPS) ≥50% (4), while the combination of platinum-based chemotherapy plus pembrolizumab is superior to chemotherapy in first-line setting, irrespective of PD-L1 status (7-9). European Medicines Agency (EMA) and Food and Drug Administration (FDA) have also approved atezolizumab in combination with carboplatin and nab-paclitaxel as first line option for non-squamous advanced NSCLCs regardless of PD-L1 expression (9-12). More recently, combinations of nivolumab and ipilimumab, an ICI targeting a different immune checkpoint CTLA-4, and of nivolumab plus ipilimumab and two cycles of platinum-doublet chemotherapy were also approved by FDA for patients with metastatic, non-oncogene driven NSCLC (11,13,14). In pretreated advanced NSCLCs, nivolumab and atezolizumab are approved irrespective of PD-L1 status (1,2,5), whereas pembrolizumab is used only in case of PD-L1 TPS ≥1% (3,9,11).

Immunotherapy has clearly improved the outcome of non-oncogene addicted advanced NSCLC. However, the magnitude of clinical benefit is highly heterogeneous and ICIs might be useless and even detrimental for some patients (15). The detection of PD-L1 TPS via immunohistochemistry has been thus far the most widely studied biomarker for predicting response to ICIs. However, such biomarker has shown a variety of limitations, which impairs its predictive value: heterogeneity of expression, different detection methods, dynamic character (16,17). This is the starting point for the quest for new predictive biomarkers (18). In this field, wide-spectrum mutational analyses performed using high-throughput sequencing tools, such as next-generation sequencing (NGS), have great potentialities. These tools permit relative quantification of tumor genetic alterations as well as their qualitative characterization and may allow for identification of genetic alterations associated with resistance to ICI.

In this regard, the role of alterations of serine-threonine kinase 11 (*STK11*) gene in NSCLC patients has raised particular interest. *STK11* is a tumor suppressor gene coding for a kinase, also known as liver kinase B1 (LKB1), involved in essential cell processes such as metabolic balance, maintenance of DNA integrity and interaction with tissue microenvironment (19-24). This kinase is inactivated in over 30% of lung cancers (25-30) and its impairment seems to be related to an immune desert tumor microenvironment and to a reduced capacity of the transformed cell to recognize DNA damages and stimulate T-cell recruitment (31). In a large retrospective study, tumor genotyping with NGS was performed in tissue and demonstrated that *KRAS*-mutated non-squamous advanced NSCLC patients carrying *STK11* mutations had worse outcome when treated with ICIs, compared to the *STK11*-wild type counterpart (32). Another study showed that *STK11* mutations in advanced NSCLC are associated with lack of durable clinical benefit (i.e., partial response or stable disease lasting more than six months) from immunotherapy (33). It is important to note that these analyses were performed in tissue samples, possibly limiting their applicability in the real-world setting. Indeed, tissue availability for molecular testing is a crucial issue in advanced NSCLC, as sometimes it is even barely enough for histological diagnosis (34-36). In addition, *STK11* genetic alterations are widespread in gene and hot-spot testing is not feasible, thus implying the need for relatively high amount of DNA for proper analysis. A possible solution might be the utilization of plasma as source of tumor genetic material.

Aim of the study was to test the role of NGS-based liquid biopsy in advanced NSCLC patients treated with ICIs. In particular, we aimed to confirm the predictive role of *STK11* mutations and co-mutations found in plasma in patients treated with ICIs. A parallel control group of patients not receiving ICIs was included.

We present our article in accordance with the STROBE reporting checklist (37) (available at http://dx.doi.org/10.21037/tlcr-20-674).

Methods

Patients

The present study is an observational prospective study, analyzing clinical and molecular data of patients consecutively prospectively screened for two studies: VISION and MAGIC-1.

At our Institution, two trials were active and provided the means to perform NGS testing both in tumor samples and in plasma: the VISION trial (NCT02864992) and the MAGIC (Monitoring Advanced NSCLC through plasma Genotyping during Immunotherapy: Clinical feasibility and application) trial.

The VISION trial is an interventional prospective trial that offered genetic pre-screening with NGS testing of tissue and/or plasma, in order to identify NSCLC patients carrying *MET* exon 14 skipping alterations or *MET* amplifications amenable of treatment with tepotinib. Primary endpoints of the trial are activity and tolerability of tepotinib (38,39).

From August 2017 to October 2019, stage IIIB/IV NSCLC patients treated at Rete Oncologica Veneta (ROV) and referring to our Institution for potential eligibility to VISION trial (NCT02864992) were prospectively screened and clinical data were collected.

Main inclusion criteria are: histologically confirmed advanced (Stage IIIB/IV) NSCLC, treatment naïve patients in first-line or pre-treated patients with no more than 2 lines of prior therapy. Main exclusion criteria are: *EGFR* activating mutations or *ALK* rearrangements that predict sensitivity to anti-EGFR or anti-ALK therapy respectively, inadequate hematological, renal and hepatic functions and relevant comorbidities, such as impaired cardiac function or known infection with human immunodeficiency virus, or an active infection with hepatitis B or C virus. Pre-screening was performed using NGS testing in tumor tissue and/or in plasma: the choice of the source biological material to be analyzed was at the discretion of the treating physician.

The Ethics Committee of our Institution approved the study on 20th February 2017. The latest version of the protocol was approved by the Ethics committee of our institution on 6th December 2018. A written informed consent was signed before any trial-related activities were carried out. Pre-screening informed consent was obtained prior to NGS testing, either in tumor tissue and/or plasma. Pre-screening informed consent version approved by our Ethics Committee is 3.0. The study was performed in accordance with the Declaration of Helsinki.

The MAGIC study is an observational prospective trial enrolling advanced, non-oncogene addicted NSCLC patients, aimed to identify genetic alterations in tumor tissue, in order to track them down in plasma and subsequently monitor their trend in relation with the kinetic of the disease (40).

From January 2017 and August 2019 advanced NSCLC patients starting systemic treatment at our Institution were prospectively enrolled. Eligibility criteria for MAGIC trial were the absence of known *EGFR* sensitizing mutations or *ALK* or *ROS-1* rearrangements, availability of tumor biopsy material collected before starting any treatment, the planning of systemic treatment and the possibility of adequate clinical and radiological follow-up. Patients were treated according to standard clinical practice with chemotherapy or ICIs. Main exclusion criteria were chemo- or radiation treatments performed prior to tissue collection. According to clinical practice, radiological evaluation was performed with iodine contrast CT-scan at baseline and during treatment.

The Ethics Committee of our Institution evaluated and approved study design and informed consent (2016/82, on 12th December 2016). Written informed consent was obtained from all patients before study entry. The study was performed in accordance with the Declaration of Helsinki.

The aim of this study (LINE, LKB1 and Immune involvement in advanced NSCLC: an Exploratory analysis) was to genetically characterize advanced NSCLC patients and in particular to define the role of LKB1 in patients' outcome while on ICI. For this purpose, patients enrolled in the MAGIC and VISION trials were considered as study population, if tested in plasma before the start of ICIs, and as control group, if never treated with ICIs. Patients tested during the course of immunotherapy were excluded. Patients' data recorded at baseline included patient demographics, Eastern Cooperative Oncology Group (ECOG) performance status (PS) at time of first line systemic treatment start, smoking history and weigh loss of more than 5% during 6 months before cancer diagnosis. Tumor data collected included histology, EGFR, ALK and ROS-1 status, as they were determined for non-squamous NSCLC, PD-L1 status, when available, and radiological staging. Information about treatments undergone by patients during the course of the disease, their response and toxicity were also collected.

The Ethics Committee of our Institution evaluated and approved this study and informed consent on 22nd January 2018 (2018/21). Written informed consent was

obtained from all patients before study entry. The study was performed in accordance with the Declaration of Helsinki.

Molecular analyses

In the frame of VISION trial, circulating tumor DNA (ctDNA) was isolated and tested from freshly collected plasma samples. ctDNA (5.0 to 30 ng) was extracted, enriched for targeted regions and underwent library preparation, in order to complete sequencing to be conducted using Illumina platform. Tumor tissue for NGS testing was obtained from archived samples or from freshly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue. *MET* alterations were searched in either plasma samples or tissue tumor samples, using Guardant360® Test, covering 73 genes and all somatic alterations recognized as potential targets by NCCN, and Oncomine™ Focus Assay (testing done by MolecularMD Inc.) covering 59 genes, respectively. Further details are described in Supplementary file (Appendix 1).

ctDNA of patients participating in MAGIC trial was isolated and tested from freshly collected plasma samples. Tumor tissue for NGS testing was obtained from archived samples or from freshly obtained FFPE tumor tissue. Plasma samples were collected at the time of first administration of systemic treatment (baseline, T1), after three or four weeks of treatment (according to the treatment schedule) (3± 1 weeks, T2), and at first radiological restaging (T3). For the present study, genetic testing performed at baseline was evaluated. ctDNA was extracted from 3 to 5 mL of plasma using the QIAamp® circulating nucleic acid Kit (QIAGEN, Hilden, Germany). CtDNA (2 to 25 ng) was used for library preparation, following the protocol of Myriapod NGS-IL 56G (Diatech Pharmacogenetics Srl; Jesi, Italy) assay. This assay covers mutational hotspots of 56 tumor-associated genes. Further details about study procedures are described in Supplementary file (Appendix 1).

Statistical analyses

The primary aim of the study was to describe the role of plasma NGS in characterizing advanced NSCLC patients receiving ICIs according to clinical practice. Primary end-point was to depict the association of the presence of the most frequent tumor-associated genetic alterations with outcome.

We analyzed the frequency of genetic alterations found and the association of the number of genetic alterations found with clinical features. Subsequently, we evaluated the impact of the presence of the most frequent genetic alterations, i.e., the ones exceeding median number of alterations found per gene, with outcome. For patients enrolled in both trials and with NGS results available from Guardant360® Test and Myriapod NGS-IL 56G Assay, we chose to use the results from the former gene panel, given its width of genome coverage. Gene variants were searched in the COSMIC database and pathogenicity was defined accordingly.

Outcome was considered in terms of overall survival (OS), as primary end-point, of immune-related progression free survival (irPFS) and of radiological response. OS was calculated from the first day of any systemic treatment to death from any cause. IrPFS was calculated from the first day of ICI treatment to the first radiological or clinical disease progression or death from any cause. Response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; disease control rate (DCR) was defined as complete response (CR) plus partial response (PR) plus stable disease (SD).

Variables were presented by using median value for continuous variables and percentages (numbers) for categorical variables and their relationship with the presence of target alteration was assessed using Mann-Whitney test, Kruskal-Wallis test and the chi-squared test as appropriate. Correlation among different gene alterations was calculated using Pearson's correlation test.

Univariate logistic regression models and results were reported using odds ratio (OR) with their 95% confidence interval (CI). Median PFS and OS were estimated by using Kaplan-Meier methods and the log-rank test was used to compare survival between groups. Hazard ratios (HR) and their 95% CI were calculated with the Cox regression method. Potential confounding effect of clinical variables was assessed by performing multivariate analysis with Cox regression method.

All the analyses were also performed in a control group of patients not receiving ICIs.

Statistical significance level was set at $P<0.05$ for all tests. All statistical analyses were performed with statistical package for the social sciences (SPSS) 20.0 software (SPSS Inc., Chicago, IL, USA).

Results

Patients and treatments

Among 234 NSCLC patients prospectively screened with

NGS in plasma, 103 patients received ICIs for advanced disease and had their plasma collected right before ICIs initiation. Among them, 72 had been pre-screened in VISION trial, 79 in the MAGIC trial; 48 of them participated in both studies. All plasma samples resulted evaluable.

Gender distribution was: 64 (62.1%) men and 39 (37.9%) women. Seventeen patients (16.5%) were never smokers, whereas 86 (83.5%) were either former (n=41; 39.8%) or active smokers (n=45; 43.7%). Median age at diagnosis of metastatic disease was 69.3 (range, 42.1–84.9) years. At the time of advanced NSCLC diagnosis, 26 (25.2%) subjects had an ECOG PS of 0 and 77 (74.8%) of ≥1. Nineteen patients (18.4%) experienced significant weight loss prior to NSCLC diagnosis. At the time of diagnosis of stage IV NSCLC, 39 subjects (37.9%) had one single site of metastasis, 39 (37.9%) had two and 25 (24.2%) had three or more sites of distant disease. Fifty-two (50.5%) patients had extra-thoracic sites of metastasis, among them 15 (14.6%) had liver metastases and 29 (28.2%) had bone metastases (*Table 1*).

Most of the patients were diagnosed with adenocarcinoma (n=80; 77.7%); the others were squamous cell carcinomas (n=20; 19.4%), non-otherwise specified carcinomas (n=2; 1.9%), or sarcomatoid carcinomas (n=1; 1.0%). PD-L1 status was available for 95 patients (92.2%). Using a 1% cut-off for PD-L1 TPS, 45 cases (47.4%) were positive. Thirty-one patients (32.6%) had PD-L1 TPS ≥50%.

For advanced disease, 19 patients (18.4%) received only one line of treatment, 66 (64.1%) two lines and 18 (17.5%) at least three lines. Immunotherapy was administered as first line treatment in 27 cases (26.2%).

A control group of 101 patients never underwent ICI treatment and had their plasma collected. Most of them were men (n=57, 56.4%) and former or current smokers (n=73, 72.3%). At the time of diagnosis of stage IV NSCLC, 31 (30.7%) had an ECOG PS 0 and 70 (69.3%) had an ECOG PS equal or higher than 1. Adenocarcinoma was the most frequent histotype (n=80, 79.2%). At the time of diagnosis of advanced disease, 49 subjects (48.5%) had one single site of metastasis, 33 (32.7%) had two and 19 (18.8%) had three or more sites of distant disease.

Clinical and pathological characteristics are displayed in *Table 1*.

Response to ICIs and patients' outcome

At the time of the analysis, median follow-up time was 20.3 (range, 5.1–57.8) months. DCR was 54.4% (partial response n=14, 13.6%, and stable disease n=42, 40.7%). Median OS was 20.8 (95% CI: 16.7–24.9) months. Median irPFS was 4.2 (95% CI: 2.3–6.1) months.

Impact of clinical features on patients' outcome

We performed univariate analysis in order to evaluate the impact on OS of known clinical prognostic features. ECOG PS (HR =1.775, 95% CI: 1.101–2.862, P=0.019), non-adenocarcinoma histology (HR =2.158, 95% CI: 1.158–4.021, P=0.015), having extrathoracic metastases (HR =2.600, 95% CI: 1.480–4.567, P=0.001) and bone metastases (HR =2.137, 95% CI: 1.197–3.816, P=0.010) had a significant impact on OS. In multivariate analysis, ECOG PS (HR =2.158, 95% CI: 1.108–4.205, P=0.024) and the presence of extrathoracic lesions (HR =2.932, 95% CI: 1.287–6.681; P=0.010) were confirmed to impact OS independently (*Table 2*).

The same variables were tested for impact on irPFS. ECOG PS (HR =2.053, 95% CI: 1.266–3.331, P=0.004) and having extrathoracic metastases (HR =2.054, 95% CI: 1.272–3.316, P=0.003) or bone metastases (HR =1.847, 95% CI: 1.120-3.046, P=0.016) had significant impact on irPFS. When multivariate analysis was performed, significance was maintained for ECOG PS (HR =2.692, 95% CI: 1.488–4.872, P=0.001) and for the presence of extrathoracic metastases (HR =2.417, 95% CI: 1.154–5.065, P=0.019) (*Table 3*).

Genetic alterations in ctDNA

The median number of mutations detected in a patient was 2 (range, 0–10). In 21 cases (20.4%) no mutation was detected. Genetic alterations were detected in fifty-three genes and among them the median number of alteration for each gene was 3 (range, 1–53) (*Figure 1*). The most commonly altered genes were: *TP53* (n=53), *KRAS* (n=22), *EGFR* (n=13), *PIK3CA* (n=11), *MET* (n=10), *STK11* (n=9), *NF1* (n=9), *CCNE1* (n=7), *ARID1A* (n=6), *BRCA2* (n=5), *RB1* (n=5), *CDKN2A* (n=5), *PTEN* (n=5), *BRAF* (n=5), *APC* (n=5), *MYC* (n=4), *CTNNB1* (n=4), *MTOR* (n=3), *FGFR1* (n=3), *AR* (n=3), *DDR2* (n=3), *KIT* (n=3), *SMAD4* (n=3), *PDGFRA* (n=3) and *IDH1* (n=3).

TP53 genetic alterations were detected in 53 cases (51.5%) and nine patients carried more than one *TP53* pathogenic variant. Among these 53 cases, two carried a variant of unknown significance (VUS) and two carried

Table 1 Patients' characteristics

Variables	Study population (n=103)	Control population (n=101)	P value*
Gender			0.407
Male	64 (62.1%)	57 (56.4%)	
Female	39 (37.9%)	44 (43.6%)	
Age (years; range)	69.3 (42.1–84.9)	69.8 (30.4–87.6)	0.767
Smoking status			
Never	17 (16.5%)	28 (27.7%)	0.053
Former and current	86 (83.5%)	73 (72.3%)	
ECOG PS			
0	26 (25.2%)	31 (30.7%)	0.458
≥1	77 (74.8%)	70 (69.3%)	
Weight loss	19 (18.4%)	21 (20.8%)	0.622
Histology			0.391
Adenocarcinoma	80 (77.7%)	80 (79.2%)	
Squamous cell carcinoma	20 (19.4%)	21 (20.8%)	
NOS carcinoma	2 (1.9%)	0 (0.0%)	
Sarcomatoid carcinoma	1 (1.0%)	0 (0.0%)	
PD-L1 test performed	95 (92.2%)	88 (87.1%)	0.394
PD-L1 positive			
Cut-off TPS ≥1%	45 (47.4%)	39 (44.3%)	0.679
Cut-off TPS ≥50%	31 (32.6%)	10 (11.4%)	0.001
Number of metastatic sites			0.377
1	39 (37.9%)	49 (48.5%)	
2	39 (37.9%)	33 (32.7%)	
≥3	25 (24.2%)	19 (18.8%)	
Sites of metastases			
Extrathoracic	52 (50.5%)	50 (49.5%)	0.933
Liver	15 (14.6%)	11 (10.9%)	0.415
Bone	29 (28.2%)	26 (25.7%)	0.698
KRAS alteration	22 (21.3%)	26 (25.7%)	0.364
TP53 alteration	53 (51.5%)	41 (40.6%)	0.200
STK11 alteration	9 (8.7%)	10 (9.9%)	0.775
KRAS/STK11 co-mutation	3 (2.9%)	6 (5.9%)	0.292
STK11/TP53 co-mutation	7 (6.8%)	4 (3.9%)	0.370
TP53/KRAS co-mutation	9 (8.7%)	14 (13.8%)	0.247
KRAS/STK11/TP53 co-mutation	2 (1.9%)	2 (2.0%)	0.325

*, statistical evaluation of variables' distribution between the populations. Chi-squared test and Mann-Whitney were used as appropriate.

Table 2 Univariate and multivariate analysis of overall survival in the study population

Variables	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Clinical variables						
Gender (female)	0.648	0.353–1.190	0.162	–	–	–
Age	1.013	0.985–1.043	0.357	–	–	–
Smoking status	1.572	0.625–3.953	0.336	–	–	–
ECOG PS	1.775	1.101–2.862	*0.019*	2.158	1.108–4.205	*0.024*
Weight loss	1.429	0.695–2.938	0.331	–	–	–
Histology (non-adenocarcinoma)	2.158	1.158–4.021	*0.015*	1.578	0.683–3.643	0.286
Number of metastases	1.199	0.917–1.567	0.185	–	–	–
Extrathoracic metastasis	2.600	1.480–4.567	*0.001*	2.932	1.287–6.681	*0.010*
Liver metastasis	2.064	0.987–4.316	0.054	–	–	–
Bone metastasis	2.137	1.197–3.816	*0.010*	0.821	0.311–2.170	0.697
Molecular variables						
Total number of gene alterations	1.154	1.034–1.288	*0.010*	1.056	0.895–1.245	0.518
KRAS alteration	0.791	0.373–1.678	0.541	–	–	–
TP53 alteration	1.606	1.220–2.115	*0.001*	2.512	1.208–5.224	*0.014*
STK11 alteration	1.208	0.971–1.503	0.090	–	–	–
KRAS/STK11 co-mutation	10.936	2.337–51.164	*0.002*	NC	–	–
STK11/TP53 co-mutation	2.415	1.008–5.784	*0.048*	1.673	0.433–6.465	0.456
TP53/KRAS co-mutation	0.890	0.215–3.681	0.872	–	–	–
KRAS/STK11/TP53 co-mutation	17.609	3.777–82.089	*<0.001*	19.834	3.242–121.326	*0.001*
FGFR alteration	5.273	1.591–17.474	*0.007*	2.348	0.484–11.397	0.289

Statistically significant P values are reported in italics. CI, confidence interval; HR, hazard ratio; NC, non-calculable.

a neutral variant (Functional Analysis through Hidden Markov Models, FATHMM, score of 0.24); the other 49 were either pathogenic or likely pathogenic (Table S1).

KRAS mutations were found in 22 cases (21.3%), with one patient only carrying a VUS mutation. Most of these mutations (n=16, 72.7%) caused a change in the amino acid residue at position 12 (G12X). *EGFR* was mutated in nine cases (8.7%); four alterations were VUS, the others were non-classical mutations. *EGFR* gene was amplified in four cases. Nine patients carried *PIK3CA* mutations: seven had a pathogenic alteration (FATHMM between 0.96 and 1.00), while two had a benign polymorphism. Furthermore, *PIK3CA* was amplified in two more cases. Three patients carried a *MET* exon 14 skipping mutation; two of these

carried also a low *MET* gene amplification. Two patients carried other pathogenic *MET* mutations, two carried neutral *MET* mutations, one had a VUS of *MET* and two had a *MET* amplification. *NF1* was also altered in nine cases (9.7%) and six of them were defined as VUS, while the others were pathogenic with a FATHMM score ranging between 0.93 and 0.99.

STK11 gene alterations were detected in nine samples (8.7%) and they were all pathogenic variants. The most common alterations were nonsense mutations (n=4, 44.5%), causing premature stop codons, followed by pathogenic missense mutations (n=3, 33.3%) and splice site single nucleotide variants (n=2, 22.2%). Three patients (2.9%) carried concomitant *KRAS/STK11* gene alterations, of

Table 3 Univariate and multivariate analysis of immune-related progression free survival

Variables	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Clinical variables						
Gender (female)	1.099	0.673–1.793	0.707	–	–	–
Age	1.014	0.989–1.041	0.271	–	–	–
Smoking status	1.315	0.653–2.648	0.444	–	–	–
ECOG PS	2.053	1.266–3.331	*0.004*	2.692	1.488–4.872	*0.001*
Weight loss	1.260	0.688–2.305	0.454	–	–	–
Histology (non-adenocarcinoma)	1.570	0.903–2.728	0.110	–	–	–
Number of metastases	1.139	0.902–1.439	0.273	–	–	–
Extrathoracic metastasis	2.054	1.272–3.316	*0.003*	2.417	1.154–5.065	*0.019*
Liver metastasis	1.204	0.629–2.305	0.575	–	–	–
Bone metastasis	1.847	1.120–3.046	*0.016*	0.898	0.430–1.874	0.775
Molecular variables						
Total number of gene alterations	1.046	0.949–1.151	0.365	–	–	–
KRAS alteration	0.854	0.469–1.557	0.607	–	–	–
TP53 alteration	1.347	1.064–1.705	*0.013*	1.822	1.057–3.141	*0.031*
STK11 alteration	1.081	0.889–1.314	0.438	–	–	–
KRAS/STK11 co-mutation	6.029	1.788–20.328	*0.004*	5.063	0.410–62.479	0.206
STK11/TP53 co-mutation	1.387	0.599–3.211	0.445	–	–	–
TP53/KRAS co-mutation	0.802	0.232–1.990	0.633	–	–	–
KRAS/STK11/TP53 co-mutation	5.088	1.189–21.613	*0.027*	5.589	1.239–25.221	*0.025*
FGFR1 alteration	5.722	1.733–18.891	*0.004*	3.538	0.968–12.923	0.056
BRCA2 mutation	6.344	1.873–21.486	*0.003*	12.302	2.668–56.727	*0.001*

Statistically significant P values are reported in italics. CI, confidence interval; HR, hazard ratio.

whom two patients (2.2%) carried also a concomitant *TP53* alteration. Moreover, five patients (4.8%) carried a *TP53* alteration with a *STK11* mutation.

Details about the other gene alterations are displayed in Table S2.

TP53, KRAS and STK11 alterations and clinical features

Among clinical and histological features, being a former or current smoker was associated with the presence of *TP53* pathogenic alterations (OR =4.020, 95% CI: 1.211–13.399,

P=0.023) (*Figure 2A*). In addition, carrying *TP53* alterations was correlated with higher risk of having extrathoracic metastases (OR =1.703, 95% CI: 1.135–2.556, P=0.010) (*Figure 2B*).

KRAS mutations were not significantly associated with any clinical features and neither were *STK11* genetic alterations.

Moreover, the presence of *KRAS* mutations was associated with PD-L1 expression in tumor cells, both using 1% (OR =4.500, 95% CI: 1.479–13.690, P=0.008) and 50% (OR =3.361, 95% CI: 1.213–9.310, P=0.020) as cut-off

210

Pavan et al. Plasma NGS in NSCLC: impact of STK11/KRAS/TP53 mutations

Figure 1 Gene alterations analyzed and their frequency in the study population. Ampl, amplification; Mut, mutation; Trans, translocation.

Figure 2 Significant correlation between clinical and pathological features and the presence of *TP53* mutation (A,B) and *KRAS* mutation (C,D). WT, wild type; Mut, mutated.

(*Figure 2C,D*). Table S3 summarizes the impact of clinical features on the presence of genetic alterations.

Association between different gene alterations

We also evaluated the presence of any association between gene alterations found in our study population. As shown in *Figure 3*, *CDKN2A*, *MTOR*, *STK11*, *CTNNB1*, *RB1* and *APC* alterations were the ones with the highest number of statistically significant associations with other gene alterations.

In particular, the presence of a mutated *CDKN2A* was positively associated with a mutated *CTNNB1* (Pearson's correlation coefficient, PC, of 0.2, P=0.029), *STK11*

(PC=0.2, P=0.018), *MTOR* (PC=0.2, P=0.029), *PTEN* (PC=0.4, P=0.001) and *PDGFRA* (PC=0.3, P=0.004). *MTOR* mutations were associated also with *APC* mutations (PC=0.2, P=0.028), *CCNE1* amplification (PC=0.6, P=0.001), *IDH1* mutation (PC=0.5, P=0.001), a mutated *RB1* (PC=0.2, P=0.028) and a mutated *PTEN* (PC=0.2, P=0.028).

A mutated *STK11*, in turn, was linked also with *CTNNB1* mutation (PC=0.3, P=0.004), *MYC* amplification (PC=0.3, P=0.005) and *CCNE1* amplification (PC=0.3, P=0.002).

Besides *STK11* and *CDKN2A*, *CTNNB1* mutations were associated with *APC* mutations (PC=0.2, P=0.028) and *MYC* amplifications (PC=0.3, P=0.011). Moreover *APC* alterations were also linked with *NF1* (PC=0.4, P=0.001) and with *TP53* mutations (PC=0.2, P=0.024), while a mutated *RB1*

Figure 3 Associations between altered genes, as found in our study population. Correlation is defined by Pearson's correlation Coefficient (PC). Only statistically significant (P<0.05) correlations are detailed. Ampl: amplification.

was also associated with *KRAS* (PC=0.2, P=0.038), *BRCA2* (PC=0.2, P=0.028) and *KIT* mutations (PC=0.6, P=0.001). With regards of *TP53* and *KRAS* mutations, they were significantly associated with *APC* (PC=0.2, P=0.024) and *RB1* (PC=0.2, P=0.038) alterations, respectively.

Details about other genes and their mutual correlations are depicted in *Figure 3*.

Impact of genetic alterations on treatment response and patients' outcome

When we considered the total number of gene alterations detected in plasma, we found that a higher number of

genetic alterations was correlated with shorter OS (HR =1.154, 95% CI: 1.034–1.288, P=0.010), but it did not affect irPFS or DCR.

Patients carrying pathogenic *TP53* alterations had significantly shorter median OS, when compared to the *TP53* wildtype counterpart (12.6 months, 95% CI: 8.5–16.8, *vs.* 26.7, 95% CI: 17.4–36.1; HR =1.606, 95% CI: 1.220–2.115, P=0.001) (*Figure 4*). *TP53* affected negatively also irPFS (3.2 months, 95% CI: 1.6-4.8 *vs.* 6.6 months, 95% CI: 1.9–11.3; HR =1.347, 95% CI: 1.064–1.705, P=0.013) (*Table 2*). DCR was not affected by *TP53* status (OR =0.745, 95% CI: 0.504–1.103, P=0.142).

The presence of *STK11* alterations was associated with

Figure 4 Impact of genetic alterations on outcome in terms of overall survival (OS). (A) Impact of *TP53* mutation on OS in the study population (treated with immune checkpoint inhibitors); (B) impact of *TP53* mutation on OS in the control group (not receiving immune checkpoint inhibitors); (C) impact of *KRAS/STK11* co-mutation on OS in the study population (treated with immune checkpoint inhibitors); (D) impact of *KRAS/STK11* co-mutation on OS in the control group (not receiving immune checkpoint inhibitors).

a trend for shorter OS (median OS: 14.9 months, 95% CI: 10.5–19.3, *vs.* 21.2 months, 95% CI: 17.3–25.1; HR =1.208, 95% CI: 0.971-1.503, P=0.090), although not reaching statistical significance. *STK11* mutational status did not affect irPFS (2.4 months, 95% CI: 2.0–2.8, *vs.* 4.4 months, 95% CI: 2.7-6.0; HR =1.081, 95% CI: 0.889–1.314, P=0.438) (*Table 2*) or DCR (OR =0.789, 95% CI: 0.550–1.132, P=0.197).

The presence of *KRAS* mutation did not significantly affect OS, irPFS and DCR (*Table 2*). This was confirmed also when we analyzed G12X mutations versus non-G12X mutations. Of interest, patients with KRAS G12X amino-acid substitution had a trend for better OS compared with non-G12X amino-acid substitution, even though it was not

statistically significant (35.6 months, 95% CI: 8.1–62.9, *vs.* 21.2 months, 95 CI%: non-evaluable, P=0.732, log-rank test).

The presence of other alterations in previously mentioned genes did not significantly affect patients' outcome (data not shown), with the exception of *FGFR1* whose alterations had a negative impact both on OS (HR =5.722, 95% CI: 1.733–18.891, P=0.004) and on irPFS (HR =5.273, 95% CI: 1.591–17.474, P=0.007), and of *BRCA2*, which affected irPFS (HR =6.344, 95% CI: 1.873–21.486, P=0.003).

We also evaluated the impact of the presence of *KRAS/STK11* co-mutation (*Figure 4*, *Tables 2,3*). This status was associated both with worse OS (5.9 months, 95% CI:

1.4–7.6, *vs.* 20.8 months, 95% CI: 16.7–29.9; HR =10.936, 95% CI: 2.337–51.164, P=0.002) and worse irPFS (1.2 months, 95% CI: 0.9–1.5, *vs.* 4.4 months, 95% CI: 2.7–6.0, HR =6.029, 95% CI: 1.788–20.328, P=0.004). *STK11/TP53* co-mutation had impact on OS (14.9 months, 95% CI: 10.3–19.5, *vs.* 21.2 months, 95% CI: 17.4–25.0; HR =2.415, 95% CI: 1.008–5.784, P=0.048), but not on irPFS (2.4 months, 95% CI: 2.1–2.8, *vs.* 4.4 months, 95% CI: 2.7–6.0; HR =1.387, 95% CI: 0.599–3.211, P=0.445). The presence of *TP53/KRAS* co-mutation did not impact either OS or irPFS. On the contrary, the presence of *KRAS/STK11/TP53* concomitant mutations negatively affected OS (1.8 months, 95% CI: not calculable, *vs.* 20.8, 95% CI: 16.9–24.8; HR =17.609, 95% CI: 3.777–82.089, P<0.001) and irPFS (1.0 month, 95% CI: not calculable, *vs.* 4.4, 95% CI: 2.7-6.1; HR =5.088, 95% CI: 1.189–21.613, P=0.027).

We performed multivariate OS analysis including ECOG PS, histology, the presence of extrathoracic or bone metastases, total number of gene alterations, *TP53* mutation, *KRAS/STK11*, *STK11/TP53* or *KRAS/STK11/TP53* co-mutation and *FGFR1* alteration as covariates. *TP53* and *KRAS/STK11/TP53* co-mutation confirmed their independent impact on OS (HR =2.512, 95% CI: 1.208–5.224, P=0.014 and HR =19.834, 95% CI: 3.242–121.326, P=0.001, respectively) (*Table 2*).

Finally, we performed multivariate irPFS analysis including ECOG PS, the presence of extrathoracic or bone metastases, *TP53* alterations, *KRAS/STK11* or *KRAS/STK11/TP53* co-mutation, *FGFR1* alteration and *BRCA2* mutation. Negative impact on patients' irPFS of *TP53*, *KRAS/STK11/TP53* co-mutation and *BRCA2* mutation was confirmed (HR =1.822, 95% CI: 1.057–3.141, P=0.031; HR =5.589, 95% CI: 1.239–25.221, P=0.025; HR =12.302, 95% CI: 2.668–56.727, P=0.001) (*Table 3*).

Genetic characterization and outcome in a control group of patients never treated with ICIs

A control population of advanced NSCLC patients (n=101) who never received immunotherapy was also evaluated. Patients' characteristics were well balanced between populations treated or not with ICIs, with the exception of enrichment in PD-L1-strong-positive (TPS ≥50%) among patients treated with ICIs (*Table 1*). At the time of the analysis, median follow-up time was 13.2 (range, 1.8–43.0) months for the control group. Median OS of control population was 16.8 months (95% CI: 13.0–20.6).

In univariate analysis, ECOG PS (HR =2.310, 95% CI:

1.222–4.365, P=0.010), weight loss (HR =4.133, 95% CI: 2.169–7.875, P<0.001), number of metastases (HR =1.703, 95% CI: 1.268–2.286, P<0.001) and having extrathoracic metastases (HR =1.958, 95% CI: 1.035–3.701, P=0.039) or bone metastasis (HR =3.181, 95% CI: 1.689–5.991, P<0.001) had significant impact on OS. Weight loss (HR =3.499, 95% CI: 1.766–6.933, P<0.001) and the presence of bone metastases (HR =3.179, 95% CI: 1.366–7.399, P=0.007) maintained independent prognostic effect in multivariate analysis.

Analyzing the impact of mutational status, *TP53* and *KRAS* mutations had a negative impact on OS (HR =1.498, 95% CI: 1.105–2.029, P=0.009, *Figure 4B*, and HR =2.999, 95% CI: 1.525–5.899, P=0.001 respectively), confirmed in multivariate test (Table S4), while *STK11* had no impact at all. Neither *STK11/KRAS*, nor *STK11/KRAS/TP53*, nor *STK11/TP53* co-mutation had any impact on patients' outcome (HR =2.180, 95% CI: 0.510–9.326, P=0.293, HR =2.411, 95% CI: 0.324–17.913, P=0.390 and HR =2.051, 95% CI: 0.628–6.698, P=0.234, respectively) (*Figures 4*). When tested in multivariate analysis, both *TP53* and *KRAS* alterations were still significantly associated with worse survival (HR =1.422, 95% CI: 1.045–1.936, P=0.025 and HR =2.701, 95% CI: 1.362–5.356, P=0.004, respectively; Table S4).

Discussion

Wide genetic characterization has the potential to provide predictive information for patients treated with ICIs, but tissue availability is often a limitation that may impair its application in clinical practice.

In the present work, we characterized patients undergoing immunotherapy, using NGS testing in liquid biopsies performed before the first ICI administration, in order to define the impact of genetic alterations found in plasma on outcome.

Since tissue availability often represents a strong limitation to wide molecular characterization, the use of plasma as the source of ctDNA is surely promising: liquid biopsy is a feasible procedure and could be easily repeated. ctDNA may also be representative of tumor burden and mirrors intrinsic tumor heterogeneity in space and time (40-45).

In our series, liquid biopsy samples were evaluable in the whole cohort and *TP53* mutation was the most frequent gene alteration, carrying also prognostic value. The presence of *TP53* mutations was associated with shorter OS both in

patients receiving ICIs and in patients who never received immunotherapy. The prognostic role of *TP53* in lung cancer is still debated. It has been studied extensively in surgical series and a meta-analysis confirmed its prognostic value in early stage disease only in adenocarcinoma histological subtype (46). In the studies included in this meta-analysis, however, samples were not tested using a high-throughput sequencing technique, such as NGS. More recently, La Fleur and colleagues used NGS to describe a significant negative impact of *TP53* alterations (HR =1.47, P=0.003) in a cohort of NSCLC treated with surgery (47). In the setting of advanced disease, a large report on over 1,400 metastatic patients showed similar results and median OS of *TP53* mutated was 8 months shorter than the wild-type counterpart (48). Other reports did not confirm significant prognostic value of *TP53* mutations in advanced NSCLC (49-51). To date, to the best of our knowledge, ours is the first report describing such correlation using only plasma as source material for NGS.

In our ICI cohort, *STK11* mutations were identified in 9% of patients, in line with previous reports (range: 8% to 13%) (47,50-52). Patients carrying a pathogenic variant of *STK11* and receiving ICIs showed a trend for shorter OS. The prognostic role of STK11 has been already investigated in tissue samples, and previous retrospective studies found a negative impact on outcome (50,52). These studies included patients treated with first-line platinum-based chemotherapy, with no details about further lines of treatment. Moreover, one of the two studies was characterized by a median follow-up time of only 7.39 months, leading to a median OS of 6.68 months (50), which looks even shorter than pre-immunotherapy historical controls (53). Furthermore, a recent post-hoc analysis by Vernieri and colleagues questioned the clinical impact of *STK11* mutations in NSCLC patients treated chemotherapy in the frame of the TAILOR trial (54). Therefore, any comparison should be made with caution. On the other hand, tissue NGS analysis in 240 patients treated with anti-PD-1/PD-L1 agents showed that *STK11* mutated status was significantly enriched in the subgroup of patients who did not obtain a durable clinical benefit, defined as not progressive disease for at least 6 months (33,55). Similarly, Guibert *et al.* evaluated 97 patients treated with ICIs using a targeted plasma NGS at treatment baseline and found that *STK11*-mutated patients derived a shorter irPFS, compared with the wild-type ones (51).

In our series, we were able to investigate the role of specific co-occurring gene mutations in modulating

STK11 function. First, we reported how *KRAS/STK11* co-mutations had a negative impact both on OS and on irPFS. No significant impact on outcome was found among patients not receiving ICIs.

The predictive role for *KRAS/STK11* co-mutations detected in tissue in patients receiving ICIs was recently depicted by Skoulidis *et al.* (56). The study included a control group of 120 patients treated with chemotherapy and showing no impact of co-mutations on outcome (56). On the other hand, potential negative prognostic impact of *KRAS/STK11* co-mutations in tissue emerged in previous studies, in which study population was heterogeneous according to treatment (47,52,57). In particular, a recent work selected a population of advanced NSCLC patients carrying *STK11* alterations (n=62) using tissue-based (n=44) or plasma-based (n=18) NGS, in order to define the impact of concomitant alterations on prognosis and confirmed the negative role of *KRAS/STK11* co-mutations in the study population, also including patients treated with first-line ICI (58). Notably, in our series we were able to describe differential impact on prognosis of *KRAS/STK11* co-mutation, according to the fact of being treated or not with ICIs. This finding confirms potential predictive role of *KRAS/STK11* co-mutations in patients treated with ICIs and validate plasma NGS testing for the identification of such alterations.

KRAS mutations are frequent alterations in NSCLC and *KRAS*-mutated disease represents a heterogeneous group. The subtype of *KRAS* mutation affects prognostic impact (59) and potentially also therapeutic options (60,61), while the presence of co-mutations modulates its cellular functions. In particular, the cross-talk between the KRAS-MAPK signalling pathway and the one of LKB1-AMPK has been investigated (62). The oncogenic path primed by *KRAS* mutation is further boosted by LKB1 inactivation, which is able to increase metastatic potentials acting on the anchorage-dependent cell-growth (23) and tumor cell differentiation (63). LKB1 inactivation in *KRAS*-mutated tumors also impairs one of the first steps of the immune-surveillance process, through the inhibition of stimulator of interferon genes (STING) pathway (64), leading to an immune-excluded tumor immune micro-environment (65).

Even though the number of patients carrying co-mutations is limited, we also depicted the impact of concomitant *KRAS/STK11/TP53* mutations on outcome, according to treatment. In this context, Bange and colleagues did not find any significant impact of *KRAS/*

STK11/TP53 co-mutations on outcome. The study population was heterogeneous according to treatment and the timing of liquid biopsy was not pre-defined and could occur over-90 days after the start of first line therapy (58).

In ICI cohort of our study, also *FGFR1* turned out to have negative impact on patients' OS and irPFS, even if it was not confirmed in multivariate analysis (*Tables 2,3*). In this field, evidence is very scanty. *FGFR1* was included in the gene panel tested in the previous series of ICI-treated patients, but no impact on outcome was reported (33,51). As shown in preclinical experiences with breast cancer cell-lines, a dysregulated FGFR1 pathway could induce an immune-suppressive microenvironment, through macrophage recruitment and increased angiogenesis (66-68). However, larger studies are needed to evaluate and eventually validate this finding in NSCLC field.

We also found that *BRCA2* pathogenic mutations negatively affected irPFS. Evidence about the impact of this alteration in lung cancer is scarce. Experiences in other neoplasms, such as breast, ovarian and prostate cancers, seem to correlate the presence of mutations affecting *BRCA2* to higher mutational burden and to a STING-mediated activation of the immune system (69), but also to an immune-suppressive tumor microenvironment (70) and to the absence of activated T-cells (71). Given to the low number of *BRCA2* mutated patients in our series, we are not able to draw any conclusion; however, the role of *BRCA2* alterations remains controversial and needs to be further evaluated in NSCLC patients, in particular when immunotherapy is administered.

Among the other most common alterations, we detected nine non-classical *EGFR* mutations (Table S2). *EGFR* common alterations (i.e., exon 19 deletions and exon 21 mutations) are associated with reduced efficacy of immunotherapy, but information about the impact of rare *EGFR* alterations on immunotherapy is unknown (72). In our series, the presence of non-classical *EGFR* mutations did not significantly affect patients' outcome.

The main strengths of our study are the consecutive enrolment of patients referred to our center, the extensive performance of liquid biopsy in a real-world population and the possibility to analyze the results according to treatment. Our control group was adequate in terms of number of patients and of clinical and pathological homogeneity with study population. NGS multi-gene screening let us also establish the role of co-mutations, whose role in modulating oncogenic pathways is known and deserves further clinical validation (32,73-75). As a

matter of fact, when analyzing *KRAS*, *STK11* and *TP53* mutations and co-mutations according to treatment, the predictive value of *STK11* co-mutation clearly emerged.

The present study has also some limitations. First, when analyzing *STK11* status, we could technically evaluate point mutations (SNV) and small insertions and deletions, but not large deletions involving the STK11 gene, nor its epigenetic modifications, that can also account for *STK11* inactivation (30,32,76). Therefore, our conclusions may underestimate the real impact of altered *STK11* on patients' response to immunotherapy. Second, the total number of *STK11*-mutated cases or carrying other co-mutations was limited. Third, regarding the NGS gene panel used to test plasma samples in our series, other important gene alterations, such the ones affecting *KEAP1*, were not included. The KEAP1 pathway has a central role in protecting cells from oxidative and electrophilic stresses (77) and is disrupted in about 15% of NSCLC (78). *KEAP1* mutational status and its epigenetic silencing are associated with poor prognosis and chemotherapeutic resistance in NSCLC (79). Furthermore, it seems to be also linked to an "immune-cold" tumor microenvironment (80,81) and, when present with a concurrent *KRAS* mutation, it was associated with shorter irPFS (57).

Conclusions

Our study depicts the role of liquid biopsy in detecting tumor genetic alterations with potential predictive impact in patients undergoing immunotherapy in clinical practice. While *TP53* mutations showed to have prognostic value, we confirmed the predictive value of *KRAS/STK11* and *KRAS/LKB1/TP53* mutations when detected in plasma.

Acknowledgments

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/tlcr-20-674

Data Sharing Statement: Available at http://dx.doi.org/10.21037/tlcr-20-674

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-674). RR serves as a current Editor-in-chief for *Translational Lung Cancer Research*. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The Ethics Committee of our Institution evaluated and approved the VISION study and informed consent on 20th February 2017 (2017/52). A written informed consent was signed before any trial-related activities were carried out. The Ethics Committee of our Institution approved MAGIC study design and informed consent on 12th December 2016 (2016/82). A written informed consent was obtained from all patients before study entry. The Ethics Committee of our Institution evaluated and approved LINE study and informed consent on 22nd January 2018 (2018/21). Written informed consent was obtained from all patients before study entry. All three studies were performed in accordance with the Declaration of Helsinki.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39.

2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.

3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.

4. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33.

5. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.

6. Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. ImmunoTargets Ther 2018;7:63-75.

7. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92.

8. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51.

9. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2018;29:iv192-237.

10. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria. Lancet Oncol 2019;20:924-37.

11. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer - National Comprehensive Cancer Network (NCCN) - 2020 Clinical Practice Guidelines - Version 8.2020. 2020.

12. Hanna NH, Schneider BJ, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2020;38:1608-32.

13. Reck M, Ciuleanu TE, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell

lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol 2020;38:abstr 9501.

14. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2019;381:2020-31.

15. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive Disease in Patients with Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors or with Single-Agent Chemotherapy. JAMA Oncol 2018;4:1543-52.

16. Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34.

17. You W, Shang B, Sun J, et al. Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37.

18. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19:133-50.

19. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.

20. Lizcano JM, Göransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004;23:833-43.

21. Wang Y-S, Chen J, Cui F, et al. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget 2016;7:73389-401.

22. Liang X, Wang P, Gao Q, et al. Exogenous activation of LKB1/AMPK signaling induces G1 arrest in cells with endogenous LKB1 expression. Mol Med Rep 2014;9:1019-24.

23. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene 2008;27:6908-19.

24. Bonanno L, Zulato E, Pavan A, et al. LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. Int J Mol Sci 2019;20:1874.

25. Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 Mutations Promote Cervical Cancer Progression. Aziz SA, editor. PLoS One 2009;4:e5137.

26. Tanwar PS, Mohapatra G, Chiang S, et al. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis 2014;35:546-53.

27. Morton JP, Jamieson NB, Karim SA, et al. LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest. Gastroenterology 2010;139:586-97.

28. Shen Z, Wen XF, Lan F, et al. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 2002;8:2085-90.

29. Gill RK, Yang SH, Meerzaman D, et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011;30:3784-91.

30. Bonanno L, De Paoli A, Zulato E, et al. LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clin Cancer Res 2017;23:3316-24.

31. Kitajima S, Ivanova E, Guo S, et al. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov 2019;9:34-45.

32. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 2018;8:822-35.

33. Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 2018;36:633-41.

34. Paz-Ares L, Langer CJ, Novello S, et al. LBA80 Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann Oncol 2019;30.

35. Powell SF, Abreu DR, Langer CJ, et al. 1483PD Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407. Ann Oncol 2019;30:v606-v607.

36. Basik M, Aguilar-Mahecha A, Rousseau C, et al. Biopsies: Next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013;10:437-50.

37. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med 2007;4:e296.

38. Paik PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with MET ex14 mutations. J Clin Oncol 2019;37:abstr 9005.

39. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-

Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020;383:931-43.

40. Zulato E, Attili I, Pavan A, et al. Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. Br J Cancer 2020;123:81-91.

41. Diaz LA Jr, Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.

42. Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med 2014;6:224ra24.

43. Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif 2019;17:100087.

44. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.

45. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol 2018;13:1248-68.

46. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 2000;6:4055-63.

47. La Fleur L, Falk-Sörqvist E, Smeds P, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer 2019;130:50-8.

48. Jiao XD, Qin BD, You P, et al. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer 2018;123:70-5.

49. Tamiya A, Koh Y, Isa S, et al. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study. Cancer Med 2020;9:2343-51.

50. Gibert J, Clavé S, Hardy-Werbin M, et al. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma. Lung Cancer 2020;140:42-5.

51. Guibert N, Jones G, Beeler JF, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer 2019;137:1-6.

52. Facchinetti F, Bluthgen MV, Tergemina-Clain G, et al. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer 2017;112:62-8.

53. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.

54. Vernieri C, Ganzinelli M, Rulli E, et al. LKB1 mutations are not associated with the efficacy of first- and second-line chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC): a post hoc analysis of the TAILOR trial. ESMO Open 2020;5:e000748.

55. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.

56. Skoulidis F, Arbour KC, Hellmann MD, et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol 2019;37:abstr 102.

57. Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res 2018;24:334-40.

58. Bange E, Marmarelis ME, Hwang WT, et al. Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11 -Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 2019;3:PO.18.00326.

59. Yu HA, Sima CS, Shen R, et al. Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. J Thorac Oncol 2015;10:431-7.

60. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019;575:217-23.

61. Herbst RS, Schlessinger J. Small molecule combats cancer-causing KRAS protein at last. Nature 2019;575:294-5.

62. Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009;100:370-5.

63. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10.

64. Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol 2015;15:760-70.

65. Givechian KB, Garner C, Benz S, et al. An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma. Oncotarget 2019;10:1840-9.

66. Reed JR, Stone MD, Beadnell TC, et al. Fibroblast

Growth Factor Receptor 1 Activation in Mammary Tumor Cells Promotes Macrophage Recruitment in a CX3CL1-Dependent Manner. Li Y, editor. PLoS One 2012;7:e45877.

67. Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016;8:299-313.

68. Ohm JE. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101:4878-86.

69. Reisländer T, Lombardi EP, Groelly FJ, et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun 2019;10:3143.

70. Jenzer M, Keß P, Nientiedt C, et al. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol Immunother 2019;68:1621-33.

71. Wen WX, Leong C-O. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. Fei P, editor. PLoS One 2019;14:e0215381.

72. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30:1321-8.

73. Bria E, Pilotto S, Amato E, et al. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget 2015;6:12783-95.

74. Rosell R, Sureda BM, Costa C, et al. Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3). Ann Oncol 2012;23:ixe22.

75. Arbour K, Shen R, Plodkowski A, et al. MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB. J Thorac Oncol 2018;13:S424.

76. Skoulidis F, Byers LA, Diao L, et al. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discov 2015;5:860-77.

77. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21:689-700.

78. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;21:689-700.

79. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.

80. Nadal E, Palmero R, Muñoz-Pinedo C. Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments. J Thorac Oncol 2019;14:1881-3.

81. Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362:eaar3593.

Plasma analysis performed in VISION trial

Circulating tumor DNA (ctDNA) was isolated and tested from freshly collected plasma samples. Cell free DNA (cfDNA) is extracted from a routine blood draw (custom collection kit with two 10 mL Streck tubes). 5.0–30 ng of ctDNA were extracted from plasma, enriched for targeted regions and undergoes digital library preparation including oligonucleotide barcoding of each strand in each individual DNA fragment. Complete sequencing was conducted using the Illumina platform (HiSeq 2500) and hg19 as the reference genome. Multi-analyte algorithms and bioinformatics were used to reconstruct the progenitor cfDNA fragment sequences. Quantitative reporting of single nucleotide variants mutant allele fraction (VAF) and gene copy numbers were reported. Genes included in Guardant360® test gene-panel (n=73) are the indicated below:

- AKT1, ALK, APC, AR, ARAF ARID1A, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND2, CCNE1, CDH1, CDK4, CDK6, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, ESR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GATA3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, APK1, MAPK3, MET, MLH1, MPL, MTOR, MYC, NF1, NFE2L2, NOTCH1, NPM1, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, PTPN11, RAF1, RB1, RET, RHEB, RHOA, RIT1, ROS1, SMAD4, SMO, STK11, TERT, TP53, TSC1 and VHL

Plasma analysis performed in MAGIC trial

Plasma samples were collected at baseline, i.e., at the time of first administration of systemic treatment and in two other time-points, as previously described by Zulato *et al.* (40). cfDNA was extracted from 3 to 5 mL of plasma using the QIAamp® circulating nucleic acid Kit (QIAGEN, Hilden, Germany). 2 to 25 ng of cfDNA were used for library preparation, following the protocol of Myriapod NGS-IL 56G (Diatech Pharmacogenetics Srl.) assay. The panel covers mutational hotspots of 56 tumor-associated genes. Sequencing was performed with the Illumina MiSeq Sequencer in paired-end mode (2×151 cycles). Myriapod NGS Data Analysis Software was used for variant calling. Single nucleotide variants mutant allele fraction (VAF) and deletions/insertions were reported. Genes included in the Myriapod® NGS 56G Onco panel panel (n=56) are indicated below:

- ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MPL, MSH6, NOTCH, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, STK11, SMAD4, SMARCB1, SMO, SRC, TP53, TSC1 and VHL

Table S1 *KRAS*, *TP53* and *STK11* gene alterations detected in study population

KRAS		TP53		STK11	
Code	Alteration	Code	Alteration	Code	Alteration
V10	Q61R	V10	R280G	V104	E256*
V54	G12A		P190R	V136	H168L
V69	G12A		P177L	V162	Splice site SNV
V79	G12A		c.920-2del	V169	K178*
V90	C80F (VUS)	V12	Y220B	V184	Splice site SNV
V96	G12V		P278A	V190	D277fs
V98	G12C	V25	T81fs	V197	E293*
V104	G12C		V274G	V199	E223*
V124	G12D		P250L	M54	G251V
V155	Q61L	V26	K120R		
V157	G12R		H214R		
V187	V14I		S392fs		
V189	G12F		R248Q		
V197	G12C		V216M		
V199	G12R	V30	Y220C		
V206	G12C	V59	C238Y		
V209	G12D	V61	I162F		
V212	G13E	V67	R337C		
V233	G12C	V79	R306*		
M129	G12C	V80	S160fs		
M289	G12V	V81	H179R		
M315	G13D	V90	F270L		
		V91	R270T (VUS)		
		V94	I50T (VUS)		
		V96	H168L		
		V104	P301fs		
		V108	R158L		
			M246V		
			L257P		
		V125	R158L		
		V126	R175H		
		V136	R273C		

KRAS		TP53		STK11	
Code	Alteration	Code	Alteration	Code	Alteration
		V142	H179R		
		V150	S240R		
		V155	W91*		
		V163	I195F		
		V169	V143fs		
		V183	H193N		
		V184	R249M		
		V190	C275Y		
		V196	E180K		
		V197	E171fs		
		V204	V157F (neutral)		
		V206	L369fs		
		V216	L111P		
		V220	V216L		
			L257Q		
			S241Y		
		V233	A159_P177delinsK		
		V237	R337P		
		V240	Splice site SNV		
		M125	C277F		
		M153	E258*		
		M240	V172D		
		M247	A159P		
		M263	M246V		
			R158L		
		M83	C275F		
			V274F (neutral)		
		M54	R333fs		
		M110	R248Q		
		M143	R273L		

KRAS		TP53		STK11	
Code	Alteration	Code	Alteration	Code	Alteration
		M191	A159P		
			L130H		
		M243	R181P		
		M276	E298*		
		M304	E343*		
		M315	K164E		
		M270	M246L		
		M320	Y163C		

*, Nonsense mutation: a point mutation that results in a premature stop codon. SNV, single nucleotide variant; Fs, frame shift. In *italics* gene alterations not considered for analysis, either being variants of unknown significance (VUS), or non-pathogenic variants.

Table S2 Other most common gene alterations detected in study population

Gene	Code	Alteration
EGFR	V18	N771_H773dup
	V26	Q812K (VUS)
	V30	P644L
	V79	Amplification 2+
	V155	E114K
	V190	S380T (VUS)
	V196	E709_T710delinsD Amplification 1+
	V199	C307S (VUS)
	V201	G652delinsER (VUS)
	M153	T785= (VUS)
	V158	A767_V769dup
	V132	Amplification 1+
	V220	Amplification 3+
MET	V61	Exon 14 skipping mutation
	V183	Exon 14 skipping mutation Amplification 1+
	V204	Exon 14 skipping mutation Amplification 1+
	V31	D1039N (VUS)
	V132	E91* E967* Amplification 2+
	V220	E34K (neutral)
	V240	R469*
	M269	S178= (neutral)
	V26	Amplification 1+
	V59	Amplification 2+
NF1	V30	L2209*
	V80	H2457R (VUS)
	V126	D1269Y (VUS)
	V137	F694L (VUS)
	V183	E524Q R1534*
	V187	L1543P
	V233	V2175I (VUS)
	V237	P2246_R2247insL (VUS)
	V240	Q1360E (VUS)

Table S2 (continued)

Gene	Code	Alteration
PIK3CA	V26	E545K
	V67	Amplification 1+
	V97	E545K
	V124	H1047R
	V196	E545K
	V201	E542K
	V216	Amplification 2+
	V233	T1025S
	M153	I391M (neutral)
	M240	I391M (neutral)
	M304	E545K
ARID1A	V13	Y454fs (VUS)
	V81	Q564* (VUS)
	V136	H782D (VUS) Q1402H (VUS)
	V157	Q1095fs (VUS)
	V196	F1245L (VUS)
	V212	M1564fs (VUS)
CCNE1	V79	Amplification 3+
	V81	Amplification 1+
	V108	Amplification 1+
	V142	Amplification 1+
	V158	Q277*
	V184	Amplification 1+
	V197	Amplification 1+
BRCA2	V125	T2350S (neutral)
	V130	T2031A (VUS)
	V136	R2888H (neutral)
	V137	L3215fs (VUS)
	V199	D1386Y
RB1	V81	R262Q
	V96	I244K (VUS)
	V199	S795S (VUS) R798fs
	V206	C706F
	V240	Splice site SNV

Table S2 (continued)

Gene	Code	Alteration
CDKN2A	V136	L130Q
	V197	D108N
	V201	R80*
	V240	R80*
	143	A118*
PTEN	V26	H123Y
	V94	R130G
	V240	S287*
	M143	D92Y
	M270	P96S
BRAF	V61	Amplification 1+
	V155	I326V
	V183	Amplification 1+
	M83	L597V
	V187	V600E
APC	V30	R332*
	V80	Y1135C (VUS)
	V190	I2083M (VUS)
	V240	N32S
	M191	S1503*
MTOR	V18	I1118V (VUS)
	V184	R1286Q
	V240	T416I (VUS)
MYC	V125	Amplification 3+
	V132	Amplification 1+
	V190	Amplification 2+
	V197	Amplification 3+
FGFR1	V52	Amplification 3+
	V125	E138K (VUS)
	V216	Amplification 3+
AR	V59	I184T (VUS)
	V216	P135T (VUS)
	V237	R856C
DDR2	V26	R611Q (VUS)
	V31	L735M (VUS)
	V94	R752H

Table S2 (continued)

Gene	Code	Alteration
KIT	V81	D327H (VUS)
	V96	E85K (neutral)
	M269	M541L (neutral)
SMAD4	V61	R361C
	V130	T349fs (VUS)
	V183	E390*
PDGFRA	V136	S91A (VUS) A90D (VUS)
	V209	K964N
	M269	V824= (neutral)
IDH1	V184	R132H
	M216	G105= (neutral)
	M237	G105= (neutral)
CTNNB1	V104	S37C
	V201	S37F S37C
	M188	S45F (VUS)

*Nonsense mutation: a point mutation that results in a premature stop codon. SNV, single nucleotide variant; Fs, frame shift. In *italics* gene alterations not considered for analysis, either being variants of unknown significance (VUS), or non-pathogenic variants.

Gene amplification is expressed as:
- Low (1+): amplification magnitude is below the 50th percentile of amplifications;
- Medium (2+): amplification magnitude is between the 50th and 90th percentiles;
- High (3+): amplification magnitude is above the 90th percentile.

Table S3 P values of chi-squared test performed between clinical features and gene alterations

	Smoker versus non-smoker	Adenocarcinoma versus other histotypes	PD-L1 TPS ≥1%	PD-L1 TPS ≥50%	Extrathoracic metastases	Liver metastases	Bone metastases
TP53	0.019	0.446	0.462	0.658	0.013	0.055	0.156
	*OR =4.020; P=0.023				*OR =1.703; P=0.010		
KRAS	0.104	0.321	0.005	0.016	0.882	0.529	0.253
			*OR =4.500; P=0.008	*OR =3.361; P=0.020			
STK11	0.163	0.095	0.559	0.630	0.340	0.705	0.796
EGFR	0.246	0.162	0.506	0.219	0.537	0.053	0.289
MET	0.004	0.335	0.937	0.302	0.242	0.565	0.655
	*OR =NC						
NF1	0.735	0.091	0.835	0.918	0.625	0.637	0.800
PIK3CA	0.841	0.511	0.654	0.520	0.459	0.738	0.943
ARID1A	0.234	0.007	0.908	0.322	0.462	0.023	0.471
						*OR =6.000; P=0.040	
CCNE1	0.926	0.093	0.465	0.934	0.462	1.000	0.471
BRCA2	0.408	0.642	0.612	0.954	0.507	0.431	0.888
RB1	0.280	0.330	0.572	0.686	0.200	0.837	0.603
CDKN2A	0.919	0.031	0.192	0.548	0.048	0.377	0.616
					*OR =NC		
PTEN	0.900	0.907	0.210	0.119	0.276	0.363	0.637
BRAF	0.087	0.276	0.068	0.011	0.361	0.639	0.354
				*OR =NC			
APC	0.280	0.897	0.028	0.116	0.719	0.837	0.626
			*OR =NC				
MTOR	0.408	0.345	0.612	0.229	0.609	0.431	0.253
MYC	0.713	0.175	0.264	0.424	0.929	0.360	0.184
FGFR1	0.486	0.061	0.504	0.954	0.609	0.431	0.888
AR	0.486	0.642	0.612	0.954	0.066	0.431	0.253
DDR2	0.486	0.345	0.092	0.229	0.066	0.431	0.253
KIT	0.411	0.069	0.518	0.978	0.596	0.424	0.166
SMAD4	0.026	0.345	0.504	0.187	0.507	0.431	0.888
	*OR =0.099; P=0.065						
PDGFRA	0.411	0.069	0.518	0.978	0.520	0.434	0.912
IDH1	0.414	0.352	0.610	0.967	0.072	0.437	0.260
CTNN1	0.705	0.276	0.053	0.166	0.947	0.363	0.354

*, for significant associations, logistic regression test was tried and performed, in order to calculate odds ratio (OR). NC, not calculable.

Table S4 Univariate and multivariate analysis of overall survival performed in the control group

	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Clinical variables						
Gender (female)	0.768	0.413–1.427	0.403	–	–	–
Age	1.006	0.979–1.033	0.679	–	–	–
Smoking status	1.913	0.876–4.177	0.103	–	–	–
ECOG PS	2.310	1.222–4.365	0.010	1.531	0.795–2.946	0.203
Weight loss	4.133	2.169–7.875	<0.001	3.499	1.766–6.933	<0.001
Number of metastases	1.703	1.268–2.286	<0.001	1.246	0.870–1.837	0.218
Extrathoracic metastasis	1.958	1.035–3.701	0.039	0.665	0.274–1.615	0.368
Liver metastasis	2.021	0.885–4.619	0.095	–	–	–
Bone metastasis	3.181	1.689–5.991	<0.001	3.179	1.366-7.399	0.007
Molecular variables						
TP53 alteration	1.498	1.105–2.029	0.009	1.422	1.045–1.936	0.025
KRAS alteration	2.999	1.525–5.899	0.001	2.701	1.362–5.356	0.004
STK11 alteration	1.166	0.922–1.475	0.199	–	–	–
KRAS/STK11 co-mutation	2.180	0.510–9.326	0.293	-	–	–
STK11/TP53 co-mutation	2.051	0.628–6.698	0.234	–	–	–
KRAS/STK11/TP53 co-mutation	2.411	0.324–17.913	0.390	–	–	–

CI, confidence interval; HR, hazard ratio.